Consensus Meeting on Methodological Considerations for Suicide Assessment and Clinical Trial Design

Statements:

Nomenclature & Classification
Instrumentation & Special Populations
Analysis of SIB Data
Design and Methodology for SIB Treatment Studies
Developing Policy and Education on SIB Assessment

Steering Committee:
Phillip Chappell
Michelle Stewart
Larry Alphs
Stephen Marder

Objective:

Convene a wide variety of stakeholders such as representatives from governmental, pharmaceutical, academic, patient, and clinical trial study settings to discuss and reach consensus on approaches to resolve key outstanding issues confronting the field.

Working Goals:
Develop consensus on
–Principles and characteristics of a standardized nomenclature and classification scheme for SIB
–Best approaches to the detection and assessment of SIB across different patient populations
–Analysis of SIB data at the study, program and meta-analytic level and the uses of Big Data methods to better understand SIB
–Design of clinical studies and drug development programs for regulatory approval of medicines to treat SIB
–Approaches to developing policies and educational initiatives to support adoption of consensus recommendations

Working Subgroups
–Nomenclature & Classification
–Instrumentation & Special Populations
–Analysis of SIB Data
–Design and Methodology for SIB Treatment Studies
–Developing Policy and Education on SIB Assessment

Meeting Structure:
Day 1:
8:00-Morning Break – Plenary Session
Post Break – 5:30 pm – Working Group Breakouts
Day 2:
8:00-1:15 – Plenary Session